Bayer Yakuhin Ltd. To Transfer Baynas Marketing Rights To Nippon Shinyaku Co., Ltd.
Published: Apr 24, 2006
Tokyo, Apr 24, 2006 (JCN) - Bayer Yakuhin and Nippon Shinyaku have reached an agreement on the sale of Baynas Tablet, Bayer's proprietary anti-allergic rhinitis drug, in Japan. Under the agreement, Bayer Yakuhin will transfer the marketing rights to the agent to Nippon Shinyaku on July 1. Baynas Tablet is an agent that antagonizes prostaglandin D2 and thromboxane A2 receptors, which cause allergic rhinitis. Initially launched in May 2005, sales of the agent reached 3 billion yen ($25.3 mil) in 2005.